Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 2, 2026Annals of OncologyOpen Access

Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trial

View Full Paper
Ask AI
Bookmark
Share

Authors

GFG. FolprechtSSS. StasikARA Reinacher-Schick

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates adjuvant chemotherapy impact on outcomes in ctDNA-positive colon cancer patients, suggesting future use of ctDNA testing.

Key Points

  • The aim is to assess the effectiveness of adjuvant chemotherapy in patients with stage II colon cancer who are ctDNA positive.
  • Patients with stage II colon cancer were tested for circulating tumour DNA (ctDNA) using an NGS-based test.
  • ctDNA-positive patients were randomized 2:1 to receive chemotherapy or observation.
  • The primary endpoint evaluated was disease-free survival (DFS) in ctDNA-positive patients.
  • DFS and overall survival (OS) were significantly lower in ctDNA-positive patients compared to ctDNA-negative patients (3-year DFS: 52% vs 87%, P < 0.001).
  • In the per-protocol analysis, patients receiving chemotherapy had improved DFS compared to those under observation (3-year DFS: 77% vs 38%, P = 0.021).
  • The primary intention-to-treat (ITT) endpoint was not met due to premature trial closure.

Cite This Study

Folprecht et al. (2026) studied this question.

synapsesocial.com/papers/6a1e734530b38c64201b68bbhttps://doi.org/10.1016/j.annonc.2026.05.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 898032007 · 448 citations
  2. 2Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study2015 · 684 citations
  3. 3Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer2022 · 1,073 citations
  4. 4ctDNA monitoring using patient-specific sequencing and integration of variant reads2020 · 204 citations